Biotechnology

Alkermes

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Alkermes released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 392.91 M (forecast USD 361.38 M), actual EPS USD -0.4 (forecast USD -0.5839)

Alkermes Completes Acquisition of Avadel Pharmaceuticals

Alkermes to Release FY2026 Q1 Earnings on May 5, Pre-Market EST; Forecast Revenue USD 361.38 M, EPS USD -0.5837

Alkermes Launches Brilliance Trial to Evaluate Aliorexton for Narcolepsy

Alcém announces Semaglutide injection in India

Alkermes released FY2025 earnings on February 25 Pre-Market (EST), actual revenue USD 1.476 B (forecast USD 1.473 B), actual EPS USD 1.43 (forecast USD 1.4782)

Alkermes released FY2025 Q4 earnings on February 25 Pre-Market EST, actual revenue USD 384.55 M (forecast USD 381.49 M), actual EPS USD 0.2906 (forecast USD 0.3422)

Alkermes to Release FY2025 Q4 Earnings on February 25, 2026, Pre-Market EST; Forecast Revenue USD 380.35 M, EPS USD 0.3288

Alkermes Advances Orexin 2 Receptor Agonist into Phase 3 and Plans Acquisition of Avidel

Avadel Pharmaceuticals' Shareholders Approve Alkermes Acquisition Proposal

Alkermes' alixorexton Receives FDA Breakthrough Therapy Designation and Advances to Phase 3 Development

BlackRock Completes Significant Voting Shares Acquisition in ALKEM

BlackRock Acquires Shares in Alkermes

Alkermes Executives Disposed of Company Stocks

Alkermes Increases Bid for Avadel Pharmaceuticals to $2.37 Billion

Alkermes Increases Bid for Avadel

Truist Financial Analyst Maintains Buy Rating on Alkermes with a Price Target of $55

Alkermes Announces Lundbeck Proposal as Top Priority

Wells Fargo Downgrades Arkema's Target Price to $37

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Alkermes FY2026 EPS Forecast Reduced by HC Wainwright

ALKS

SBIO

ARKG

LABU

HC Wainwright has lowered its FY2026 EPS forecast for Alkermes plc from ($0.41) to ($0.44). The firm maintains a 'Neutral' rating with a price target of $43.00. Other analysts have varied opinions, with Bank of America raising its target to $36.00 and UBS Group increasing it to $48.00. Alkermes shares opened at $37.00, with a market cap of $6.17 billion.

Market Beat

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR S&P Biotech

Health Care Select Sector SPDR

VG Health

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Bank of America

ROYAL BANK OF CANADA

UBS Group AG

Wells Fargo

PNC Financial Services

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Alkermes has reported positive results from the Phase III REVITALYZ study of Lumryz (sodium oxybate) for treating idiopathic hypersomnia (IH), a rare sleep disorder. The trial met its primary endpoint, showing significant improvements in sleepiness scores compared to placebo. Alkermes plans to file a supplemental new drug application with the FDA by year-end, although Lumryz is currently not approved for IH. The company aims to enhance treatment options for sleep disorders through ongoing research.

WorldPharmaceuticals

Shutterstock

Alkermes reports encouraging data from Phase III study of Lumryz

Wells Fargo analyst maintained a Buy rating on Alkermes today and set a price target of $44.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Wells Fargo, Alkermes also received a Buy from Robert W. Baird’s Luke Herrmann in a report issued today. However, on the same day, H.C. Wainwright reiterated a Hold rating on Alkermes (NASDAQ: ALKS).

Tip Ranks

Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)

Healthcare stocks saw gains late Tuesday, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF rising about 2%. Notable movements included a 3% drop in West Pharmaceutical Services due to a cyberattack, and a 7% increase in Alkermes after positive trial results for Lumryz. Sonida Senior Living's stock decline was deemed unwarranted by RBC, which raised its price target. Dr. Reddy's Laboratories plans to launch a generic Ozempic in Canada, with its shares falling 5.3%.

Fidelity

Dr Reddys Laboratories

West Pharmaceutical

SPDR S&P Health

iShares Global Healthcare

SPDR S&P Health Equip

iShares US Pharma

iShares US Medical Devices

Sonida Senior Living

Novo Nordisk AS

Sector Update: Healthcare Stocks Advance Late Afternoon

Alkermes Inc. shares rose after positive phase 3 results for LUMRYZ in treating excessive daytime sleepiness linked to idiopathic hypersomnia. The study met all primary and secondary endpoints, prompting analysts to raise price targets, with an average target of $45.67. The stock is currently trading at $37.84, marking a 6.68% increase and a new 52-week high. Alkermes plans to file a supplemental New Drug Application with the FDA by the end of 2026, although marketing for idiopathic hypersomnia is restricted until March 2028 due to a prior settlement.

benzinga_article

S&P 500

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

AGIO

Healthcare stocks experienced gains on May 12, 2026, with the NYSE Healthcare Index up 2.1% and the State Street Healthcare Select Sector SPDR ETF rising 2.2%. Alkermes saw a 5% increase after positive trial results for its Lumryz oral suspension. RBC Capital Markets upgraded Sonida Senior Living's price target to $45, noting its strong Q1 results, leading to a 1.5% rise in shares. Agios Pharmaceuticals rose 1% after submitting a New Drug Application for mitapivat to treat sickle cell disease.

Agios Pharmac

Sector Update: Healthcare Stocks Gain in Afternoon Trading

JAZZ

Alkermes has achieved a significant milestone with its $2.37 billion acquisition of Avadel, as the phase 3 study of Lumryz for idiopathic hypersomnia met all primary and secondary endpoints. This positive outcome allows Alkermes to plan for FDA approval by the end of 2026, with a potential launch in early 2028. Lumryz aims to compete with Jazz Pharmaceuticals' Xywav, the only FDA-approved treatment for this condition. Alkermes anticipates Lumryz could generate sales between $350 million and $370 million in its first year.

Fiercepharma

Jazz Pharma

Avadel Pharma

Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH

Alkermes announced that its Phase 3 trial for Lumryz, an oral suspension for treating idiopathic hypersomnia, met all primary and key secondary endpoints. The medication showed significant reductions in excessive daytime sleepiness and improved disease severity compared to placebo. Participants switched to placebo experienced symptom worsening. Alkermes plans to submit a supplemental new drug application to the FDA by year-end. The company's shares rose 1.3% in premarket trading.

Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment

Alkermes(ALKS.US)